ReviewInternational journal of hematology2013
PET/CT in malignant lymphoma: basic information, clinical application, and proposal.
Review in International journal of hematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 14 citations in OpenAlex.
- Assessment of the nature of residual masses at end of treatment in lymphoma patients using volume perfusion computed tomography.European radiology · 2014Trial
- Article
- Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma.BMC cancer · 2015Article
- Successful treatment of histiocytic sarcoma with induction chemotherapy consisting of dose-escalated CHOP plus etoposide and upfront consolidation auto-transplantation.International journal of hematology · 2014Article
- Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma.International journal of hematology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coregistered fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) provides functional and morphologic data useful for the management of lymphoma. PET/CT is a promising tool in initial staging/re-staging, monitoring post-treatment recurrence/exacerbation, and evaluating prognosis at mid-treatment use [interim PET/CT (iPET/CT)]. Many multicenter studies are currently underway to investigate the effectiveness and safety of stratified treatment protocols using iPET/CT. Thus, the establishment of a system focusing on standardization of image quality through established protocols for scanning or quality control (QC) of the acquired data and organization of a core laboratory facility to promote standardization would be beneficial. Uniformity of image quality across multiple institutions can be guaranteed through optimization of imaging conditions and appropriate QC of PET/CT scanners to ensure standardization. Further research is required to ensure the standardization of PET/CT protocols used in the management of malignant lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.